halenaquinone profile

halenaquinone: RN given refers to (S)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	370346
CHEMBL ID	513747
SCHEMBL ID	12464240
MeSH ID	M0392564

Synonym
x57wt4ej87 ,
unii-x57wt4ej87
halenaquinone
86690-14-4
NSC643407 ,
NCI60_014670
nsc-643407
CHEMBL513747 ,
bdbm50323927
helenaquinone
SCHEMBL12464240
DTXSID50235769
(s)-12b-methyl-1h-tetrapheno[5,4-bc]furan-3,6,8,11(2h,12bh)-tetraone
(1s)-1-methyl-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2(11),3,6,9,13(20),15-hexaene-5,8,12,17-tetrone
1h-benzo(6,7)phenanthro(10,1-bc)furan-3,6,8,11(2h,12bh)-tetrone, 12b-methyl-, (12bs)-
(+)-halenaquinone
(12bs)-12b-methyl-1h-benzo(6,7)phenanthro(10,1-bc)furan-3,6,8,11(2h,12bh)-tetrone
(1s)-1-methyl-14-oxapentacyclo(11.6.1.02,11.04,9.016,20)icosa-2,4(9),6,10,13(20),15-hexaene-5,8,12,17-tetrone
AKOS040748517

Excerpt	Reference	Relevance
" Taken together, our results suggested that the antileukemic effect of HQ is ROS-mediated mitochondrial apoptosis combined with the inhibitory effect on HDAC and topoisomerase activities."	( Tackling the Cytotoxic Effect of a Marine Polycyclic Quinone-Type Metabolite: Halenaquinone Induces Molt 4 Cells Apoptosis via Oxidative Stress Combined with the Inhibition of HDAC and Topoisomerase Activities. Chen, YC; Du, YC; El-Shazly, M; Juan, YS; Lee, MG; Lu, MC; Shih, SP; Su, JH; Sung, PJ; Wen, ZH; Wu, YC; Yang, JC, 2015)	0.65

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Phospholipase A2	Apis mellifera (honey bee)	IC50 (µMol)	3.7000	0.0700	3.8570	7.5000	AID497174; AID568203
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.9300	0.0005	0.4716	10.0000	AID497176; AID568205
Protein farnesyltransferase subunit beta	Homo sapiens (human)	IC50 (µMol)	0.9300	0.0005	0.2177	2.5000	AID497176; AID568205
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	3.7000	0.0002	0.6603	10.0000	AID497174
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
transforming growth factor beta receptor signaling pathway	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesylation	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein geranylgeranylation	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
skeletal muscle acetylcholine-gated channel clustering	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
positive regulation of tubulin deacetylation	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
positive regulation of deacetylase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clustering	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
lipid metabolic process	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein farnesylation	Protein farnesyltransferase subunit beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein farnesyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein geranylgeranyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
Rab geranylgeranyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
microtubule binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
receptor tyrosine kinase binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
alpha-tubulin binding	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
molecular adaptor activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
CAAX-protein geranylgeranyltransferase activity	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein farnesyltransferase activity	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein binding	Protein farnesyltransferase subunit beta	Homo sapiens (human)
zinc ion binding	Protein farnesyltransferase subunit beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
plasma membrane	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
CAAX-protein geranylgeranyltransferase complex	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
microtubule associated complex	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
protein farnesyltransferase complex	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
cytoplasm	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	Homo sapiens (human)
cytosol	Protein farnesyltransferase subunit beta	Homo sapiens (human)
microtubule associated complex	Protein farnesyltransferase subunit beta	Homo sapiens (human)
protein farnesyltransferase complex	Protein farnesyltransferase subunit beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID568206	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 48 hrs	2011	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4	Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID1167331	Inhibition of sRANKL-induced TRAP activity in mouse RAW264 cells by p-nitrophenolate release based TRAP assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
AID568207	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs	2011	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4	Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID497179	Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia.
AID338248	Inhibition of Rous sarcoma virus v-Src	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Inhibitors of protein tyrosine kinase pp60v-src: sterol sulfates from the brittle star Ophiarachna incrassata.
AID1847088	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Recent advances of quinones as a privileged structure in drug discovery.
AID1167330	Inhibition of sRANKL-induced TRAP activity in mouse RAW264 cells at 20 uM by p-nitrophenolate release based TRAP assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
AID1167335	Inhibition of sRANKL-induced IkappaB24 degradation in mouse RAW264 cells at 10 to 50 uM pre-treated for 2 hrs before sRANKL stimulation measured 15 mins after sRANKL stimulation by Western blotting method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
AID497174	Inhibition of bee venom phospholipase A2 after 5 mins by spectrophotometric analysis	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia.
AID568208	Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs	2011	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4	Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID497176	Inhibition of human FTase after 15 mins by fluorimetric analysis	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia.
AID629415	Inhibition of GST-tagged T cell factor4/beta casein interaction assessed as reduction in alkaline phosphatase level	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Neopetrosiquinones A and B, sesquiterpene benzoquinones isolated from the deep-water sponge Neopetrosia cf. proxima.
AID1167332	Inhibition of sRANKL-induced osteoclastogenesis in mouse RAW264 cells assessed as reduction in TRAP-positive multinuclear osteoclasts formation at 20 uM incubated for 4 days by TRAP assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
AID568203	Inhibition of bee venom phospholipase A2 after 5 mins by spectrophotometric analysis	2011	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4	Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID1167336	Inhibition of sRANKL-induced AKT phosphorylation in mouse RAW264 cells at 20 uM pre-treated for 2 hrs before sRANKL stimulation measured 15 mins after sRANKL stimulation by Western blotting method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
AID497175	Inhibition of Saccharomyces cerevisiae FTase after 15 mins by fluorimetric analysis	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia.
AID568205	Inhibition of human FTase after 15 mins by fluorimetric analysis	2011	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4	Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID1167334	Inhibition of sRANKL-induced IkappaB24 degradation in mouse RAW264 cells at 20 uM pre-treated for 2 hrs before sRANKL stimulation measured 15 mins after sRANKL stimulation by Western blotting method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
AID497177	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 48 hrs	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia.
AID568204	Inhibition of Saccharomyces cerevisiae FTase after 15 mins by fluorimetric analysis	2011	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4	Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID497178	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia.
AID1167333	Inhibition of chymotrypsin-like activity of proteasome in rat liver using Suc-Leu-Leu-Val-Tyr-MCA fluorogenic substrate	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Halenaquinone inhibits RANKL-induced osteoclastogenesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (7.69)	18.2507
2000's	5 (38.46)	29.6817
2010's	6 (46.15)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (7.69%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (92.31%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.05	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
hypericin [no description available]	3.41	1
quinone benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).	7.11	1	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.03	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.43	2	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
sennidin a dihydroxydianthrone: aglycone of senna glycosides	3.41	1
xestoquinone xestoquinone: structure given in first source; RN given refers to the (S)-isomer; RN for cpd without isomeric designation not available 5/91; isolated from the sea sponge Xestospongia sapra	7.42	2
wortmannin [no description available]	2	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
fti 276 FTI 276: a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; FTI-277 is the methyl ester derivative of FTI-276	2.06	1	methionine derivative
manoalide manoalide: phospholipase A2 inhibitor; sesterterpene from marine sponge L. variabilis; structure given in first source. manoalide : A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2.	2.46	2	butenolide; lactol; sesterterpenoid	EC 3.1.1.4 (phospholipase A2) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; metabolite
cyclozonarone cyclozonarone: structure in first source	2.06	1
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.11	1

Condition	Relationship Strength	Studies
Plasmodium falciparum Malaria [description not available]	2.05	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.05	1
Infectious Diseases [description not available]	3.23	1
Benign Neoplasms [description not available]	3.23	1
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	3.23	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.23	1

halenaquinone

Description

Cross-References

Synonyms (19)

Research Excerpts

Compound-Compound Interactions

Protein Targets (4)

Inhibition Measurements

Biological Processes (9)

Molecular Functions (10)

Ceullar Components (6)

Bioassays (22)

Research

Studies (13)

Market Indicators

Research Demand Index: 17.68

Study Types

halenaquinone

Description

Cross-References

Synonyms (19)

Research Excerpts

Compound-Compound Interactions

Protein Targets (4)

Inhibition Measurements

Biological Processes (9)

Molecular Functions (10)

Ceullar Components (6)

Bioassays (22)

Research

Studies (13)

Market Indicators

Research Demand Index: 17.68

Study Types

Related Drugs (12)

Related Conditions (6)